Myriad Genetics (MYGN) Tops Q4 EPS by 21c

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.12, $0.21 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $189.4 million versus the consensus estimate of $165.4 million.

“This was another solid quarter for Myriad Genetics as we delivered strong revenue growth and grew earnings ahead of our initial expectations, an important step towards demonstrating our ability to achieve our goal of sustainable long-term growth and profitability,” said Paul J. Diaz, president and CEO. “These results reflect the hard work of our teammates, and their dedication to meeting the needs of our patients and provider partners, as we continue to advance our mission to empower every individual with the genetic answers inside each of us.”

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Nolan’s ’The Odyssey’ eyes $200M global debut, benefiting IMAX and theater stocks
• Meritage Hospitality posts Q2 loss amid restructuring charges